Smartleaf Asset Management
GPCR icon

Smartleaf Asset Management’s Structure Therapeutics GPCR Stock Holding History

Smartleaf Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$556 Hold
17
– – ﹤0.01% 3316
2026
Q2 		$879 Hold
17
– – ﹤0.01% 3120
2026
Q1 		$747 Buy
+17
New +$1.16K ﹤0.01% 3164

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return
Peregrine Capital Management
Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Smartleaf Asset Management's GPCR Position: Q3 2026 in Review

Smartleaf Asset Management held its Structure Therapeutics (GPCR) position steady in Q3 2026 at 17 shares worth $556. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Smartleaf Asset Management first reported a position in GPCR in Q1 2026 and has held it in 3 quarters since. The position peaked at $879 in Q2 2026. 67 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Smartleaf Asset Management held 17 shares of Structure Therapeutics worth $556 as of Q3 2026.
  • Smartleaf Asset Management left its Structure Therapeutics share count unchanged in Q3 2026.
  • Structure Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3316 holding.
  • Smartleaf Asset Management first reported a position in Structure Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Structure Therapeutics position peaked at $879 in Q2 2026.
  • 67 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.